FCGR2B and FCRLB gene polymorphisms associated with IgA nephropathy
Xu-jie Zhou1, Fa-juan Cheng, Yuan-yuan Qi
1Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, PR China.
Plos One
|April 18, 2013
Summary
Genetic variations in Fc receptor genes are linked to IgA nephropathy (IgAN) susceptibility in a Chinese population. Specific polymorphisms correlate with disease risk and clinical manifestations, suggesting a role in IgAN pathogenesis.
Area of Science:
- Immunology
- Genetics
- Nephrology
Background:
- IgA nephropathy (IgAN) is characterized by immune complex deposition in the kidneys.
- Fc gamma receptors (FcγRs) play a role in immune complex-mediated injury and clearance.
Purpose of the Study:
- To investigate the association between polymorphisms in the FCGR gene locus and IgAN in a large Chinese cohort.
- To explore the potential role of Fc receptor gene variants in IgAN pathogenesis.
Main Methods:
- Genotyping of 60 single nucleotide polymorphisms (SNPs) within the FCGR gene locus in 2100 IgAN patients and 2100 healthy controls.
- Statistical analysis including conditional and linkage disequilibrium analyses.
- Expression quantitative trait loci (eQTL) analysis to assess functional significance.
Main Results:
- 15 out of 60 SNPs (25%) in the FCGR locus were associated with IgAN susceptibility.
- FCGR2B rs12118043 and FCRLB rs4657093 showed significant associations, acting as independent signals.
- Specific genotypes correlated with clinical features like proteinuria, gross hematuria, serum creatinine levels, and estimated glomerular filtration rate (eGFR).
- eQTL analysis indicated that protective genotypes were associated with lower gene expression, supporting functional relevance.
Conclusions:
- Fc receptor gene polymorphisms are associated with susceptibility to IgA nephropathy.
- These genetic variations may play a pathogenic role in IgAN through altered Fc receptor function and expression.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:31Immunoglobulin-like Cell Adhesion Molecules
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...